Suchergebnisse - "rucaparib"

PubPharm (404)

71

Rucaparib and olaparib for the treatment of prostate cancer : A clinician's guide to choice of therapy

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2022

von Keisner, S.

72

Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma : A Case Report

enthalten in: Cureus | 2022

von Biswas, G.

ErratumIn: Cureus. 2022 Nov 17;14(11):c82. - PMID 36415472

73

Imaging PARP with [18F]rucaparib in pancreatic cancer models

enthalten in: European journal of nuclear medicine and molecular imaging | 2022

von Chan, C. | Chen, Z. | Destro, G. | +9

CommentIn: Radiol Imaging Cancer. 2022 Sep;4(5):e229018. - PMID 36112035

74

Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors : Synthetic Lethal Strategies That Impact Overall Survival

enthalten in: Cancers | 2022

von Xie, T. | Dickson, K. | Yee, C. | +4

75

18F]rucaparib to Image PARP in Pancreatic Cancer Models

enthalten in: Radiology. Imaging cancer | 2022

von Tan, K.

CommentOn: Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3668-3678. - PMID 35614267

76

Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy

enthalten in: International journal of clinical pharmacology and therapeutics | 2022

von Mengato, D. | Cancanelli, L. | Di Spazio, L. | +3

77

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer : results from the phase 2 CheckMate 9KD trial

enthalten in: Journal for immunotherapy of cancer | 2022

von Fizazi, K. | Retz, M. | Petrylak, D. | +24

CommentIn: J Urol. 2023 Apr;209(4):807-809. - PMID 36695094

78

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium

enthalten in: Gynecologic oncology | 2022

von Jackson, C. | Moore, K. | Cantrell, L. | +12

79

The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers : A Systematic Review

enthalten in: International journal of molecular sciences | 2022

von Lau, C. | Seow, K. | Chen, K.

80

Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2022

von Hatch, R. | Patel, S. | Cambareri, C. | +2